HLA-binding Properties of Tumor Neoepitopes in Humans

Overview

Journal Cancer Immunol Res

Specialties Allergy & Immunology
Oncology

Date 2014 Jun 5

PMID 24894089

Citations 117

Authors

Edward F Fritsch

Mohini Rajasagi

Patrick A Ott

Vladimir Brusic

Nir Hacohen

Catherine J Wu

Affiliations

Soon will be listed here.

Abstract

Cancer genome sequencing has enabled the rapid identification of the complete repertoire of coding sequence mutations within a patient's tumor and facilitated their use as personalized immunogens. Although a variety of techniques are available to assist in the selection of mutation-defined epitopes to be included within the tumor vaccine, the ability of the peptide to bind to patient MHC is a key gateway to peptide presentation. With advances in the accuracy of predictive algorithms for MHC class I binding, choosing epitopes on the basis of predicted affinity provides a rapid and unbiased approach to epitope prioritization. We show herein the retrospective application of a prediction algorithm to a large set of bona fide T cell-defined mutated human tumor antigens that induced immune responses, most of which were associated with tumor regression or long-term disease stability. The results support the application of this approach for epitope selection and reveal informative features of these naturally occurring epitopes to aid in epitope prioritization for use in tumor vaccines.

Citing Articles

Personalized Immunity: Neoantigen-Based Vaccines Revolutionizing Hepatocellular Carcinoma Treatment.

Aggeletopoulou I, Pantzios S, Triantos C Cancers (Basel). 2025; 17(3).

PMID: 39941745 PMC: 11815775. DOI: 10.3390/cancers17030376.

Attention-aware differential learning for predicting peptide-MHC class I binding and T cell receptor recognition.

Niu R, Wang J, Li Y, Zhou J, Guo Y, Shang X Brief Bioinform. 2025; 26(1).

PMID: 39883517 PMC: 11781218. DOI: 10.1093/bib/bbaf038.

Tumor Neoepitope-Based Vaccines: A Scoping Review on Current Predictive Computational Strategies.

Rocha L, Guimaraes P, Carvalho M, Ruiz J Vaccines (Basel). 2024; 12(8).

PMID: 39203962 PMC: 11360805. DOI: 10.3390/vaccines12080836.

Oxidized Melanoma Antigens Promote Activation and Proliferation of Cytotoxic T-Cell Subpopulations.

Clemen R, Miebach L, Singer D, Freund E, von Woedtke T, Weltmann K Adv Sci (Weinh). 2024; 11(33):e2404131.

PMID: 38958560 PMC: 11434111. DOI: 10.1002/advs.202404131.

Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.

Kumari K, Singh A, Chaudhary A, Singh R, Shanker A, Kumar V Vaccines (Basel). 2024; 12(5).

PMID: 38793749 PMC: 11125796. DOI: 10.3390/vaccines12050498.

References

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C . Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18(8):1254-61. DOI: 10.1038/nm.2883. View

Coulie P, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M . A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995; 92(17):7976-80. PMC: 41269. DOI: 10.1073/pnas.92.17.7976. View

Akatsuka Y, Nishida T, Kondo E, Miyazaki M, Taji H, Iida H . Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med. 2003; 197(11):1489-500. PMC: 2193899. DOI: 10.1084/jem.20021925. View

Takenoyama M, Baurain J, Yasuda M, So T, Sugaya M, Hanagiri T . A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer. 2005; 118(8):1992-7. DOI: 10.1002/ijc.21594. View

Sykulev Y, Joo M, Vturina I, Tsomides T, Eisen H . Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996; 4(6):565-71. DOI: 10.1016/s1074-7613(00)80483-5. View

de Rijke B, van Horssen-Zoetbrood A, Beekman J, Otterud B, Maas F, Woestenenk R . A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest. 2005; 115(12):3506-16. PMC: 1297240. DOI: 10.1172/JCI24832. View

RAMMENSEE H, Bachmann J, Emmerich N, Bachor O, Stevanovic S . SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999; 50(3-4):213-9. DOI: 10.1007/s002510050595. View

Yanover C, Bradley P . Large-scale characterization of peptide-MHC binding landscapes with structural simulations. Proc Natl Acad Sci U S A. 2011; 108(17):6981-6. PMC: 3084072. DOI: 10.1073/pnas.1018165108. View

Purbhoo M, Irvine D, Huppa J, Davis M . T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol. 2004; 5(5):524-30. DOI: 10.1038/ni1058. View

10.

Slager E, Honders M, van der Meijden E, van Luxemburg-Heijs S, Kloosterboer F, Kester M . Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood. 2006; 107(12):4954-60. DOI: 10.1182/blood-2005-09-3883. View

11.

Fremont D, Matsumura M, Stura E, Peterson P, Wilson I . Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science. 1992; 257(5072):919-27. DOI: 10.1126/science.1323877. View

12.

Dolstra H, Fredrix H, Maas F, Coulie P, Brasseur F, Mensink E . A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 1999; 189(2):301-8. PMC: 2192993. DOI: 10.1084/jem.189.2.301. View

13.

Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis J, Fitzgerald E . Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 2001; 166(4):2871-7. DOI: 10.4049/jimmunol.166.4.2871. View

14.

Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell M . Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res. 2002; 8(12):3696-701. View

15.

Zorn E, Hercend T . A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol. 1999; 29(2):592-601. DOI: 10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2. View

16.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

17.

Bystryn J, Zeleniuch-Jacquotte A, Oratz R, Shapiro R, Harris M, Roses D . Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res. 2001; 7(7):1882-7. View

18.

den Haan J, Meadows L, Wang W, Pool J, Blokland E, Bishop T . The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998; 279(5353):1054-7. DOI: 10.1126/science.279.5353.1054. View

19.

Morton D, Foshag L, Hoon D, Nizze J, Famatiga E, Wanek L . Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992; 216(4):463-82. PMC: 1242654. DOI: 10.1097/00000658-199210000-00010. View

20.

Senzer N, Kaufman H, Amatruda T, Nemunaitis M, Reid T, Daniels G . Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009; 27(34):5763-71. DOI: 10.1200/JCO.2009.24.3675. View